PTC Thera starts clinical trials of PTC124

18 July 2004

PTC Therapeutics of the USA says that it has initiated a Phase Iclinical trial of PTC124, a small-molecule drug which is initially under evaluation for the treatment of cystic fibrosis and Duchenne muscular dystrophy.

The Phase I study will evaluate the safety, tolerability and pharmacokinetic profile of PTC124 in healthy volunteers. In preclinical studies, the agent was found to be orally-available and well-tolerated, noted the firm.

PTC124 targets nonsense mutations, with 15% of the cases of DMD and 10% of the cases for CF being due to these single-point alterations in the DNA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Company Spotlight